Fig. 11
From: CXCL1 promotes colon cancer progression through activation of NF-κB/P300 signaling pathway
C646 treatment inhibited MC38CXCL1+/+ colon cancer tumor progression. a Experimental protocol for measuring the effect of C646 treatment in subcutaneous graft colon cancer models. b–d Tumor growth curve after treatment with C646 (MC38 WT, MC38CXCL1−/−, MC38CXCL1+/+). Administered by intraperitoneal injection every three days. Each data point is the mean ± SD (n = 5). **P < 0.01, ****P < 0.0001